Clerico A, Iervasi G, Mariani G
Laboratory of Cardiovascular Endocrinology, CNR Institute of Clinical Physiology, Pisa, Italy.
Horm Metab Res. 1999 Sep;31(9):487-98. doi: 10.1055/s-2007-978782.
Cardiac natriuretic peptides (ANP, BNP, and biologically active peptides of the N-terminal proANP1-98) are differently regulated in their production/secretion patterns and clearance rates; consequently, the assay for these peptides may provide complementary (or even different) pathophysiological and/or clinical information. The assay for cardiac natriuretic peptides has been utilized in clinical conditions associated with expanded fluid volume. In particular, this assay can be useful in discriminating between normal subjects and patients in different stages of heart failure and can also be considered a prognostic indicator of long-term survival in patients with heart failure and/or after acute myocardial infarction. Non-competitive immunometric assays (such as two-site IRMAs), even if more expensive, seem to be preferable to RIAs for routinary assay of cardiac peptide hormones because they generally have a better degree of sensitivity, accuracy, and precision.
心脏利钠肽（心房钠尿肽、脑钠肽以及氨基末端前心房钠尿肽1-98的生物活性肽）在其产生/分泌模式和清除率方面受到不同的调节；因此，对这些肽的检测可能会提供互补的（甚至是不同的）病理生理和/或临床信息。心脏利钠肽检测已用于与体液量增加相关的临床情况。特别是，该检测有助于区分正常受试者和处于不同心力衰竭阶段的患者，也可被视为心力衰竭患者和/或急性心肌梗死后患者长期生存的预后指标。非竞争性免疫分析方法（如双位点免疫放射分析），即使成本更高，但对于心脏肽激素的常规检测似乎比放射免疫分析更可取，因为它们通常具有更高的灵敏度、准确性和精密度。
